

PCT/US00/05364

FIGURE 1

Medium	Status	CA 15-3 U/mg of protein	erb units/mg of protein	p53 pmol/mg of protein	CD pmol/mg of protein	EGFR fmol/mg of protein	Total Protein mg/ml
Saliva	Controls (n=15)	2.27±1.54	Not detectable	177.1 ±61.3	26.29±17.22	1.03 ±0.69	1.25±0.82
	Benign (n=8)	2.22±1.95	Not detectable	180.7 ±70.78	40.57±13.05	0.37 ±0.31	1.44±0.92
	Ca in situ (n=12)	5.26±4.12 [†]	51.3±43.96 [†]	134.6 ±63.8	34.5±27.95	0.92 ±0.8	1.71±0.79
Serum	Controls (n=15)	16.17 ±4.64	Not detectable	14.2±7.9	67.5 ±35.61	8.5 ±8.45	24.54±13.86
	Benign (n=8)	15.25±5.04	Not detectable	14.63 ±8.8	45.0±20.98	3.52 ±1.89	27.33±14.23
	Ca in situ (n=12)	24.68±10.9 ^{††}	81.68±111.77 ^{††}	8.9 ±7.7	63.17±38.4	5.63 ±3.10	29.23 ±11.08

FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 7




Figure 8

Mean and Standard Error of the Mean (S.E.M.) Values for c-erbB-2									
Characteristics	Healthy Controls			Benign Tumors			Malignant Tumors		
	n	age	Mean (S.E.M.)	n	age	Mean (S.E.M.)	n	age	Mean (S.E.M.)
Saliva c-erbB-2	57	39.6	94.70 (± 8.39)	41	45.0	99.72 (± 10.94)	30	50.8	222.22 (± 19.22)
Saliva c-erbB-2 (Units/mg protein)	57	39.6	71.13 (± 6.07)	41	45.0	63.75 (± 7.00)	30	50.8	143.58 (± 11.53)
Salivary Protein (mg/ml)	56	39.3	1.48 (± 0.09)	41	45.0	1.58 (± 0.08)	30	50.8	1.67 (± 0.10)
Salivary CA 15-3 (Units/ml)	42	38.0	3.19 (± 0.52)	33	43.9	7.23 (± 1.58)	30	50.8	10.90 (± 3.44)
Salivary Flow Rates (ml/min.)	56	39.6	1.90 (± 0.12)	41	44.3	1.48 (± 0.12)	30	50.8	1.15 (± 0.13)
Serum c-erbB-2	57	39.6	1472.15 (± 78.78)	41	44.3	1515.63 (± 155.48)	30	50.8	3490.67 (± 364.48)
Serum c-erbB-2 (Units/mg protein)	57	39.6	28.04 (± 0.63)	41	44.3	33.05 (± 3.44)	30	50.8	85.97 (± 9.31)
Serum CA 15-3 (Units/ml)	42	38.0	10.88 (± 0.74)	33	43.9	15.91 (± 0.88)	30	50.8	41.49 (± 10.65)
Serum Protein (mg/ml)	56	39.3	53.04 (± 1.41)	44	44.3	42.90 (± 1.16)	30	50.8	42.15 (± 1.58)

Figure 9

Frequency Distribution for Questionnaire Data					
Characteristic	Controls	Benign Tumors	Malignant Tumors	p-value	
n	57	44	30	--	
Tobacco Usage	--	--	--	2.40E-06	
Yes	3	15	16	--	
No	54	29	14	--	
Race	--	--	--	0.00063	
Caucasian	38	13	12	--	
African - American	19	31	18	--	
Systemic Diseases	--	--	--	0.334	
Yes	16	17	10	--	
No	41	23	20	--	
Prescribed Medications	--	--	--	0.449	
Yes	25	23	16	--	
No	32	18	14	--	
Menopausal Status	--	--	--	0.00016	
Premenopausal	40	19	9	--	
Perimenopausal	0	10	17	--	
Postmenopausal	17	15	4	--	

Figure 10

Mean and Standard Error of the Mean (S.E.M.) Values Values for c-erbB-2 Among Varying Malignant Tumor Stages					
Characteristic		Saliva		Serum	
	n	c-erbB-2 Units/ml Mean (S.E.M.)	c-erbB-2 Units/mg protein Mean (S.E.M.)	c-erbB-2 Units/mg protein Mean (S.E.M.)	c-erbB-2 Units/mg protein Mean (S.E.M.)
T1	7	211.15 (± 25.91)	133.75 (± 10.27)	3428.13 (± 564.29)	95.57 (± 16.83)
>T1	16	190.50 (± 19.36)	137.01 (± 17.85)	3680.15 (± 605.42)	89.32 (± 14.60)
Mean and Standard Error of the Mean (S.E.M.) Values Values for c-erbB-2 Among Node Positive and Node Negative Cancer Patients					
	n	c-erbB-2 Units/ml Mean (S.E.M.)	c-erbB-2 Units/mg protein Mean (S.E.M.)	c-erbB-2 Units/ml Mean (S.E.M.)	c-erbB-2 Units/mg protein Mean (S.E.M.)
Node Negative	16	192.70 (± 21.02)	119.52 (± 12.74)	2296.36 (± 308.42)	87.44 (± 8.83)
Node Positive	7	227.25 (± 14.36)	192.42 (± 29.19)	5308.55 (± 2066.35)	126.63 (± 49.54)

Figure 11

Cutoff Values, Sensitivity, Specificity, and Percent Area Under Curve for Salivary and Serum c-erbB-2 and CA 15-3 Concentrations					
Characteristics	Cutoff Value	Sensitivity	Specificity	Percent Area Under Curve	
Saliva c-erbB-2	110	0.87	0.65	75.7	
Saliva c-erbB-2 (Units/mg protein)	100	0.77	0.77	76.7	
Salivary CA 15-3	4	0.62	0.79	70.5	
Serum c-erbB-2	2000	0.94	0.60	76.7	
Serum c-erbB-2 (Units/mg protein)	50	0.84	0.68	76.0	
Serum CA 15-3	20	0.75	0.44	62.2	




Figure 12a




Figure 12b




Figure 13a




Figure 13b




Figure 14a




Figure 14b

FIG. 15

Figure 15




Figure 16

